Augmenting the MHC II antigen-presentation pathway with epigenetic therapy in epithelial ovarian cancer von Turner, T.B, Meza-Perez, S, Peabody, J.E, Smith, H.J, Norian, L.A, Buchsbaum, D.J, Straughn, J.M, Randall, T, Arend, R.C

Volltext

Wnt pathway inhibition by niclosamide: A therapeutic target for ovarian cancer von Walters Haygood, C.L, Li, Y, Kurpad, C, Gangrade, A, Straughn, M, Buchsbaum, D.J

Volltext

Pazopanib Combined With Radiation: An In Vivo Model von Meredith, R.F, Raisch, K.P, Buchsbaum, D.J, Spencer, S.A

Volltext

Ovarian cancer ascites stem cell population compared to primary tumor von Arend, R.C, Londono-Joshi, A, Kurpad, C, Katre, A.A, Conner, M.G, Landen, C.N, Straughn, J.M, Buchsbaum, D.J

Volltext

133 (PB121): A novel pan-RAS inhibitor (ADT-1004) with superior efficacy over mutation-specific KRAS inhibitors in mouse models of pancreatic cancer von Bandi, D.S.R., Nagaraju, G.P., Foote, J.B., Keeton, A., Chen, X., Berry, K.L., Maxuitenko, Y.Y., Manne, U., Buchsbaum, D.J., Piazza, G.A., El-Rayes, B.F.

Volltext

127 (PB115): Survival benefit and tumor regression with a dual RAS/β-catenin inhibitor, ADT-030, in murine models of pancreatic and lung cancer von Bandi, D.S.R., Nagaraju, G.P., Foote, J.B., Keeton, A., Chen, X., Berry, K.L., Maxuitenko, Y.Y., Manne, U., Buchsbaum, D.J., Piazza, G.A., El-Rayes, B.F.

Volltext

Inhibiting the wnt/β-catenin pathway modulates immune response in ovarian cancer von Doo, D.W., Londono, A., Moore, D.J., Katre, A.A., Straughn, J.M., Buchsbaum, D.J., Norian, L.A., Cooper, S.J., Arend, R.C.

Volltext

Loss of N-Myc interactor promotes epithelial–mesenchymal transition by activation of TGF-β/SMAD signaling von Devine, D J, Rostas, J W, Metge, B J, Das, S, Mulekar, M S, Tucker, J A, Grizzle, W E, Buchsbaum, D J, Shevde, L A, Samant, R S

Volltext

40 von Long, J.W, Derosier, L.C, Vickers, S.M, Sellers, J, Wang, W, Arnoletti, J.P, Buchsbaum, D.J

Volltext

96 von Tzeng, C.D, Frolov, A, Howard, J.H, Vickers, S.M, Buchsbaum, D.J, Heslin, M.J, Arnoletti, J.P

Volltext

Inhibiting the wnt/β-catenin pathway modulates immune response in ovarian cancer von Londono, A., Doo, D.W., Moore, D.J., Bao, R., Katre, A.A., Lin, C.Y., Straughn, J.M., Buchsbaum, D.J., Norian, L.A., Luke, J.J., Cooper, S.J., Arend, R.C.

Volltext

Inhibition of the Wnt/β-catenin pathway enhances anti-tumor immunity in ovarian cancer von Doo, D.W., Meza-Perez, S., Londono, A., Boone, J.D., Moore, D.J., Hudson, C., Betella, I., Luke, J.J., Yang, E.S., Birrer, M.J., Starenki, D., Buchsbaum, D.J., Norian, L.A., Randall, T., Arend, R.C.

Volltext

45 von Derosier, L.C, Buchsbaum, D.J, Sellers, J, Huang, Z.Q, Oliver, P.G, Wang, W, Kurt, Z, Vickers, S.M

Volltext

Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus von Kaliberov, S A, Kaliberova, L N, Buchsbaum, D J, Curiel, D T

Volltext

Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation von McNally, L R, Rosenthal, E L, Zhang, W, Buchsbaum, D J

Volltext

CRAdRGDflt-1L24 virotherapy in combination with chemotherapy of experimental glioma von Kaliberova, L.N, Krendelchtchikova, V, Harmon, D.K, Stockard, C.R, Petersen, A.S, Markert, J.M, Gillespie, G.Y, Grizzle, W.E, Buchsbaum, D.J, Kaliberov, S.A

Volltext

Enhancement of glioma radiation therapy and chemotherapy response with targeted antibody therapy against death receptor 5 von Fiveash, J.B., Gillespie, G.Y., Buchsbaum, D.J.

Volltext

45: Treatment with a monoclonal death receptor-5 antibody and Irinotecan increases survival in a radiologically verified model of pancreatic cancer von Derosier, L.C., Buchsbaum, D.J., Sellers, J., Huang, Z.Q., Oliver, P.G., Wang, W., Kurt, Z., Vickers, S.M.

Volltext

40: TRA-8 (TRAIL-R2 antibody) based combination chemotherapy produces a survival benefit in a pancreatic cancer orthotopic model von Long, J.W., Derosier, L.C., Vickers, S.M., Sellers, J., Wang, W., Arnoletti, J.P., Buchsbaum, D.J.

Volltext

96: Analysis of aberrant epidermal growth factor receptor (EGFR) pathway signaling in pancreatic cancer patients: Implications for anti-EGFR therapy von Tzeng, C.D., Frolov, A., Howard, J.H., Vickers, S.M., Buchsbaum, D.J., Heslin, M.J., Arnoletti, J.P.

Volltext